Ernexa Therapeutics annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ernexa Therapeutics R&D Spending Growth & History (ERNA)
Ernexa Therapeutics's r&d spending was $4.2M for fiscal 2025.
View full Ernexa Therapeutics company overviewErnexa Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.2M | −$448,000 | −9.73% |
| 2024 | 2024-12-31 | $4.6M | −$1.3M | −22.23% |
| 2023 | 2023-12-31 | $5.9M | −$4.5M | −43.03% |
| 2022 | 2022-12-31 | $10.4M | −$2.3M | −18.21% |
| 2021 | 2021-12-31 | $12.7M | $8.8M | +221.56% |
| 2020 | 2020-12-31 | $4.0M | $3.9M | +15096.15% |
| 2019 | 2019-12-31 | $26,000 | −$46,000 | −63.89% |
| 2018 | 2018-12-31 | $72,000 | −$67,000 | −48.20% |
| 2017 | 2017-12-31 | $139,000 | — | — |
Ernexa Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.8M | $1.7M | +145.77% |
| Q1 2026 | 2026-03-31 | $1.9M | $606,000 | +46.29% |
| Q4 2025 | 2025-12-31 | $676,000 | −$482,000 | −41.62% |
| Q3 2025 | 2025-09-30 | $1.0M | $34,000 | +3.40% |
| Q2 2025 | 2025-06-30 | $1.1M | $149,000 | +15.10% |
| Q1 2025 | 2025-03-31 | $1.3M | −$149,000 | −10.22% |
| Q4 2024 | 2024-12-31 | $1.2M | −$202,000 | −14.85% |
| Q3 2024 | 2024-09-30 | $1.0M | −$386,000 | −27.83% |
| Q2 2024 | 2024-06-30 | $987,000 | −$512,000 | −34.16% |
| Q1 2024 | 2024-03-31 | $1.5M | −$216,000 | −12.90% |
| Q4 2023 | 2023-12-31 | $1.4M | −$602,000 | −30.68% |
| Q3 2023 | 2023-09-30 | $1.4M | −$3.6M | −72.05% |
| Q2 2023 | 2023-06-30 | $1.5M | −$186,000 | −11.04% |
| Q1 2023 | 2023-03-31 | $1.7M | −$108,000 | −6.06% |
| Q4 2022 | 2022-12-31 | $2.0M | −$2.3M | −53.82% |
| Q3 2022 | 2022-09-30 | $5.0M | $3.5M | +232.86% |
| Q2 2022 | 2022-06-30 | $1.7M | −$3.7M | −68.98% |
| Q1 2022 | 2022-03-31 | $1.8M | $249,000 | +16.24% |
| Q4 2021 | 2021-12-31 | $4.2M | — | — |
| Q3 2021 | 2021-09-30 | $1.5M | $567,471 | +61.45% |
| Q2 2021 | 2021-06-30 | $5.4M | — | — |
| Q1 2021 | 2021-03-31 | $1.5M | — | — |
| Q3 2020 | 2020-09-30 | $923,529 | — | — |
Ernexa Therapeutics r&d spending trends
Over the last five fiscal years, Ernexa Therapeutics's r&d spending increased from $4.0M to $4.2M, a change of $205,000. The latest reported quarter, Q2 2026, shows $2.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics source filings ↗